Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Promising OPMD Therapy | Benitec's BB-301 shows potential for disease modification in OPMD, with encouraging results from the first treated patient at the six-month mark |
Clinical Trial Progress | Explore Benitec's ongoing BB-301 trial, including successful dosing of a second patient and plans for a third, with significant data expected in Q1 2025 |
Financial Outlook | Benitec's $40 million private placement extends cash runway through 2025, supporting continued clinical development. Analyst price target: $16.00 |
Market Opportunity | Delve into Benitec's potential to capture a significant share of the OPMD treatment market, with BB-301 positioned as a possible first-in-class therapy |
Metrics to compare | BNTC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBNTCPeersSector | |
---|---|---|---|---|
P/E Ratio | −9.1x | −2.5x | −0.6x | |
PEG Ratio | −0.16 | 0.04 | 0.00 | |
Price/Book | 4.3x | 3.0x | 2.6x | |
Price / LTM Sales | - | 0.7x | 3.2x | |
Upside (Analyst Target) | 81.8% | 138.1% | 46.3% | |
Fair Value Upside | Unlock | 18.4% | 6.1% | Unlock |